posted on 2011-03-31, 01:51authored byJennifer D. Watkins, Nagadenahalli B. Siddappa, Samir K. Lakhashe, Michael Humbert, Anton Sholukh, Girish Hemashettar, Yin Ling Wong, John K. Yoon, Wendy Wang, Francis J. Novembre, Francois Villinger, Chris Ibegbu, Kalpana Patel, Davide Corti, Gloria Agatic, Fabrizia Vanzetta, Siro Bianchi, Jonathan L. Heeney, Federica Sallusto, Antonio Lanzavecchia, Ruth M. Ruprecht
(A) Experimental design. Group 1A infant RM (n = 4) were infused twice with 50 mg/kg of HGN194 on days −1 and 7. Group 1B (n = 2) received twice 1 mg/kg of HGN194. Four RM served as untreated controls. On day 0, all 10 animals were challenged intrarectally with 18 AID50 of SHIV-1157ipEL-p. (B) Plasma viral RNA loads after high-dose rectal challenge with SHIV-1157ipEL-p using a quantitative RT assay (detection limit: 50 copies/ml). (C) Average plasma mAb concentrations during the course of the study for Group 1A. (D) Plasma HGN194 concentration for Group 1B. Arrows in C and D indicate mAb treatments. Experiments in C and D were repeated twice or trice.